These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 28738235)

  • 1. Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.
    Vogel A; Hofheinz RD; Kubicka S; Arnold D
    Cancer Treat Rev; 2017 Sep; 59():54-60. PubMed ID: 28738235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
    Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer.
    Weinberg BA; Marshall JL; Salem ME
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):630-8. PubMed ID: 27487107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
    Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing beyond the second-line setting in metastatic colorectal cancer.
    Grothey A; Marshall JL; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):1-19. PubMed ID: 31730588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
    Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib: A Review in Metastatic Colorectal Cancer.
    Dhillon S
    Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
    Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
    Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
    Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
    Saeed A; Tabernero J; Parikh A; Van den Eynde M; Karthaus M; Gerlinger M; Wang Z; Wang G; Smith R; Hecht JR
    Future Oncol; 2024; 20(24):1733-1743. PubMed ID: 39041200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Regorafenib in patients with metastatic colorectal cancer: a review and an update].
    Zaniboni A; Mansueto G
    Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.